Novo Nordisk A/S Drops as New Eli Lilly and Company Drug Threatens Victoza
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Novo Nordisk A/S (NOVOB) fell the most among benchmark stocks in Copenhagen trading after Bank of America Merrill Lynch said the diabetes drug company’s Victoza medicine faces “a real threat” from an Eli Lilly & Co. (LLY) product. Novo fell as much as 1.9 percent, the biggest drop in the Nasdaq OMX Copenhagen 20 index. The stock retreated 1.5 percent to 918 kroner at 11:34 a.m. in the Danish capital, with trading volume at 47 percent of the three-month daily average. The stock was also today’s biggest loser in the Stoxx Health Care index of 35 companies.
Help employers find you! Check out all the jobs and post your resume.
Novo Nordisk A/S (NOVOB) fell the most among benchmark stocks in Copenhagen trading after Bank of America Merrill Lynch said the diabetes drug company’s Victoza medicine faces “a real threat” from an Eli Lilly & Co. (LLY) product. Novo fell as much as 1.9 percent, the biggest drop in the Nasdaq OMX Copenhagen 20 index. The stock retreated 1.5 percent to 918 kroner at 11:34 a.m. in the Danish capital, with trading volume at 47 percent of the three-month daily average. The stock was also today’s biggest loser in the Stoxx Health Care index of 35 companies.
Help employers find you! Check out all the jobs and post your resume.